A5014298155- Inflammatory Bowel Disease
- Microscopic Colitis
- Health Systems, Economic Evaluations, Quality of Life
- Acute Lymphoblastic Leukemia research
- Eosinophilic Esophagitis
- Pregnancy and Medication Impact
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal disorders and treatments
- Autoimmune and Inflammatory Disorders
- Health, psychology, and well-being
- Childhood Cancer Survivors' Quality of Life
- Diagnosis and treatment of tuberculosis
- Organ Transplantation Techniques and Outcomes
- Immunodeficiency and Autoimmune Disorders
- Mindfulness and Compassion Interventions
- Liver Diseases and Immunity
- Pancreatitis Pathology and Treatment
- Adolescent and Pediatric Healthcare
- Optimism, Hope, and Well-being
- Liver Disease Diagnosis and Treatment
- Mental Health via Writing
- Diet and metabolism studies
- Celiac Disease Research and Management
- Cystic Fibrosis Research Advances
- Hepatitis C virus research
Barwon Health
2012-2025
Deakin University
2020-2023
Geelong Hospital
2012-2022
Eastern Health
2013-2019
Monash University
2014-2019
Covance (United Kingdom)
2019
Alfred Health
2014-2018
Box Hill Hospital
2018
Moscow Clinical Scientific Center
2016
The Alfred Hospital
2014-2015
Objective We evaluated the influence of renin–angiotensin system (RAS) on intestinal inflammation and fibrosis. Design Cultured human colonic myofibroblast proliferation collagen secretion were assessed following treatment with angiotensin (Ang) II Ang (1–7), their receptor antagonists candesartan A779, ACE inhibitor captopril. Circulating RAS components in patients without IBD. Disease outcomes IBD treated inhibitors blockers (ARBs) retrospective studies. Results Human was reduced by (1–7)...
Summary Background Diet is fundamental to the care of irritable bowel syndrome (IBS). However, some approaches are not appropriate for individuals experiencing psychological symptoms. Aims To assess feasibility a Mediterranean diet in IBS and its impact on gastrointestinal Methods We recruited adults with Rome IV mild or moderate anxiety and/or depressive symptoms an unblinded 6‐week randomised controlled trial. Patients were counselling habitual diet. collected symptom data, dietary data...
Abstract Background The optimal dosing strategy of infliximab (IFX) in Acute Severe Ulcerative Colitis (ASUC) is unknown. We compared intensified and standard dose IFX strategies ASUC. Methods In this open-label randomised trial (NCT02770040), patients from 13 Australian centres with intravenous steroid-refractory ASUC were to receive a first 10mg/kg or 5mg/kg 1:2 ratio. Patients the group (intensified induction [II]) received second at day 7 earlier time non-response; all re-randomised 1:1...
Regional variations in inflammatory bowel disease (IBD) rates have been observed. Limited epidemiological data are available from Australasia. IBD prevalence never assessed an Australian population-based setting. In addition, there few historical incidence to allow assessment of rate changes. The aims were calculate Australia's first rates, reassess local and establish a inception cohort.An observational, prospective study was performed assess July 2010 June 2011 geographically defined...
The outcomes of acute severe ulcerative colitis [ASUC] appear to be dependent on early intervention with the first and/or further infliximab [IFX] doses, although parameters guide decision-making remain uncertain. To assess whether serum/faecal IFX levels and inflammatory biomarkers after dose can predict ASUC outcomes. This prospective pilot study consecutively recruited inpatients steroid-refractory ASUC, who then received 1–3 rescue doses [5 mg/kg per dose] at discretion treating...
Whether therapeutic drug monitoring for adalimumab needs to be performed at trough has not been defined.To determine intra-patient drug-level variation and identify modulating patient disease factors.In this prospective observational study, adult patients with Crohn's established on maintenance had levels measured repeatedly according pre-defined schedules (visit 1: day 4-6, visit 2: 7-9, trough: 13-14) across two consecutive fortnightly cycles. Disease activity was assessed using...
Abstract Background The ability to predict failure of infliximab (IFX) in acute severe ulcerative colitis (ASUC) is crucial identify patients who may benefit from dose-escalation, sequential rescue or early colectomy. Methods PREDICT-UC (NCT02770040) was a randomised controlled trial that compared IFX dosing strategies ASUC.1 Clinical factors and biomarkers were collected daily between day 0 3 post-IFX assessed on their (Lichtiger score ≥10 14) 3-month Stepwise logistic regression used...
Abstract Background Faecal calprotectin (FCP) is routinely used in the management of inflammatory bowel disease; however, its role acute severe ulcerative colitis (ASUC) unclear. We aimed to evaluate relationship between FCP and outcomes ASUC. Methods included ASUC patients who were screened/randomised as part PREDICT-UC (NCT02770040), a randomised controlled trial that evaluated escalated infliximab (IFX) dosing strategies steroid-refractory ASUC.1 Stool was collected at screening, day 0...
Abstract Background The utility of infliximab (IFX) therapeutic drug monitoring (TDM) in acute severe ulcerative colitis (ASUC) is unclear. We aimed to assess whether IFX levels are associated with outcomes ASUC. Methods PREDICT-UC (NCT02770040) was a randomised controlled trial that compared dosing strategies 138 steroid-refractory ASUC patients.1 Serum and faecal were quantified by ELISA (MabTrack level infliximab, Essange Reagents, Netherlands) after conclusion the correlated outcomes:...
This study explored the lived experience of people with inflammatory bowel disease and anxiety/depression. It utilised a deductive biopsychosocial framework. Overall, 24 patients 20 healthcare professionals from two countries participated. In United Kingdom, main themes included (1) bidirectional relationship between mental health, (2) need for integration (3) lack awareness about disease. Australia, 'vicious cycle' psychosocial stigma hidden Better communication around illness is essential...
Background and aim: Individuals with inflammatory bowel disease (IBD) suffer higher rates of anxiety depression than the general population, however, few psychological interventions are designed for this population. Acceptance Commitment Therapy (ACT), aimed to increase flexibility, may be useful address unique concerns IBD sufferers. This study explore stakeholder perspectives on an ACT-based intervention prototype tailored people comorbid and/or depressive symptoms.Methods: An Intervention...
Abstract Background Faecal calprotectin (FC) is an accurate biomarker of disease activity in inflammatory bowel (IBD), yet the cost/resource implications incorporating FC into ‘real‐world’ practice remain uncertain. Aim To evaluate utility clinical decision‐making and on healthcare costs IBD. Methods Retrospective data, including colonoscopy/other investigations, medication, admission surgical were collected from hospital records compared between two groups: pre‐FC historical cohort...
IgG4 sclerosing cholangitis (IgG4-SC) is the biliary component of multisystem IgG4-related disease. We aimed to investigate clinical features, demographics, treatment response and outcomes IgG4-SC in a large Australian cohort.We conducted nationwide retrospective cohort via Liver Association Clinical Trials Network (ALA-CRN). 39 sites were invited participate. was defined by diagnostic criteria established Japanese Biliary 2012. Data collected on patient demographic, laboratory information,...
'Dose tailoring' of anti-tumour necrosis factor alpha (TNF-α) therapy in Crohn disease (CD), by dose escalation, or shortening dosing intervals, has been suggested to regain clinical response following a flare proportion patients. However, reported outcome data are sparse and none exists from Australia.In an observational multicentre, retrospective study, the impact anti-TNF-α tailoring on corticosteroid use, need for surgery physician perception efficacy was examined real-world setting at...